Home  /  Resource Library  /  Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy

Results of a study examining the use of granulocyte-colony stimulating factor in combination with Brentuximab Vedotin for first line treatment of Hodgkin lymphoma.